SCHEMBL5934657

SCHEMBL5934657

CC(C)(C)c1cccc(NC(=O)c2ccc(-c3ccc(F)c(F)c3)nc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 2/20 0.54
▸ HDAC6 Q9UBN7 2/20 0.54
▸ HDAC3 O15379 1/20 0.54
▸ KCNK9 Q9NPC2 1/20 0.47
▸ TRPV1 Q8NER1 2/20 0.47
▸ PTPN1 P18031 1/20 0.46
▸ PTPN6 P29350 1/20 0.46
▸ PTPN11 Q06124 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ CYP11B1 P15538 1/20 0.45
▸ CYP11B2 P19099 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ P2RX1 P51575 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5934381 0.88 HPGDS (0.55) HDAC8HDAC6HDAC3KCNK9TRPV1
SCHEMBL5934188 0.87 HDAC3 (0.56) HDAC8HDAC6HDAC3KCNK9TRPV1
SCHEMBL5934585 0.86 HDAC3 (0.55) HDAC8HDAC6HDAC3KCNK9TRPV1
SCHEMBL5934471 0.86 MEN1 (0.57) HDAC8HDAC6HDAC3MEN1KMT2A
SCHEMBL5934592 0.86 HDAC3 (0.55) HDAC8HDAC6HDAC3KCNK9TRPV1
SCHEMBL5934416 0.86 HDAC3 (0.57) HDAC8HDAC6HDAC3KCNK9TRPV1
SCHEMBL5934425 0.84 HDAC3 (0.55) HDAC8HDAC6HDAC3KCNK9TRPV1
SCHEMBL5934477 0.82 TRPV1 (0.56) HDAC8HDAC6HDAC3TRPV1SMN1; SMN2
SCHEMBL5934224 0.82 TP53 (0.55) HDAC8HDAC6HDAC3TRPV1MEN1
SCHEMBL5934639 0.82 HDAC8 (0.53) HDAC8HDAC6HDAC3KCNK9TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575918-A2 SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-21 — — EP claimed
WO-2004056774-A2 SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-08 — — WO claimed
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues HCAR2, AHR, HCAR3 HDAC8 740/4885HDAC6 1243/4885HDAC3 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback